Interferon Alpha for Refractory Pseudophakic Cystoid Macular Edema (Irvine-Gass Syndrome)

被引：15

作者：

Dimopoulos, Spyridon ^{[1
]}

Deuter, Christoph M. E. ^{[1
]}

Blumenstock, Gunnar ^{[2
]}

Zierhut, Manfred ^{[1
]}

Dimopoulou, Anastasia ^{[1
]}

Voykov, Bogomil ^{[1
]}

Bartz-Schmidt, Karl-Ulrich ^{[1
]}

Doycheva, Deshka ^{[1
]}

机构：

[1] Univ Hosp Tuebingen, Ctr Ophthalmol, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany

[2] Eberhard Karls Univ Tuebingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2020年 / 28卷 / 02期

关键词：

Cataract surgery; interferon alpha; Irvine-Gass syndrome; macular edema; treatment; RISK-FACTORS; SURGERY; PHACOEMULSIFICATION;

D O I：

10.1080/09273948.2019.1585883

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To assess the efficacy and safety of systemic interferon alpha-2a (IFN) for refractory pseudophakic cystoid macular edema (PCME). Methods: Retrospective observational study. The primary outcome was the decrease of central retinal thickness (CRT). Secondary endpoints were the improvement of best-corrected visual acuity (BCVA) and the assessment of IFN-related side effects. Results: Twenty-four eyes of 20 patients were included. The median CRT was 513 mu m (range 220-980 mu m) at baseline and decreased to 190 mu m (range 140-520 mu m) at the last follow-up visit (p < 0.001). Reduction of CRT greater than 100 mu m was observed in 22 eyes (92%). The median BCVA (logMAR) increased statistically significant from 0.5 (range 0.2-1.5) at baseline to 0.3 (0-0.8) at the last follow-up (p < 0.001). The BCVA improved in 18 eyes (75%) and remained stable in five eyes (21%). No severe treatment-related side effects occurred. Conclusion: IFN is a very effective agent for treatment of refractory PCME.

引用

页码：315 / 321

页数：7

共 50 条

[31] Intravitreal pegaptanib sodium for Irvine-Gass syndrome
Querques, G.
Iaculli, C.
Delle Noci, N.
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2008, 18 (01) : 138 - 141
[32] Intravitreal ranibizumab for the treatment of irvine-gass syndrome
Chatziralli, I.
Parikakis, E.
Peponis, V.
Tsiotra, V.
Mitropoulos, P.
ACTA OPHTHALMOLOGICA, 2014, 92
[33] Intravitreal bevacizumab (avastin) for refractory pseudophakic cystoid macular edema
Mason, John O., III
Albert, Michael A., Jr.
Vail, Rachel
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03): : 356 - 357
[34] Macular hole formation in a patient with Irvine-Gass syndrome: coincidence or rare complication?
Moschos, Marilita M.
Gatzioufas, Zisis
Rotsos, Tryfon
Symeonidis, Chrysanthos
Song, Xuefei
Seitz, Berthold
CLINICAL OPHTHALMOLOGY, 2013, 7 : 1437 - 1439
[35] OUR EXPERIENCE IN THE TREATMENT OF THE IRVINE-GASS SYNDROME
ARCINIEGAS, CA
MOSQUEDA, FM
OPHTHALMOLOGICA, 1982, 184 (01) : 21 - 25
[36] Isolated foveolar detachment in Irvine-Gass syndrome
Greene, A. B.
Del Priore, L. V.
Iranmanesh, R.
BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (09) : 1210 - 1211
[37] Intravitreal Ranibizumab for the Treatment of Irvine-Gass Syndrome
Mitropoulos, Panagiotis G.
Chatziralli, Irini P.
Peponis, Vasileios G.
Drakos, Evangelos
Parikakis, Efstratios A.
OCULAR IMMUNOLOGY AND INFLAMMATION, 2015, 23 (03) : 225 - 231
[38] Treatment of pseudophakic cystoid macular edema
Agostini, H. T.
Hansen, L. L.
Feltgen, N.
OPHTHALMOLOGE, 2007, 104 (05): : 425 - +
[39] Very-late-onset-Irvine-Gass-SyndromVery late onset Irvine-Gass syndrome
J. Jakob-Girbig
L. Hahner
D. Meller
Der Ophthalmologe, 2021, 118 : 1267 - 1271
[40] Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema
Conway, MD
Canakis, C
Livir-Rallatos, C
Peyman, GA
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2003, 29 (01): : 27 - 33

← 1 2 3 4 5 →